Anti-thymocyte globulin (ATG) is polyclonal, containing Ab specificities capable of binding to various immune-cell subsets implicated in the pathogenesis of GVHD, including T cells, B cells, natural killer cells, monocytes/macrophages, neutrophils and DC. We wished to determine which ATG specificities are important for GVHD prevention. We measured day 7 serum levels of 23 ATG specificities in 120 hematopoietic cell transplant recipients whose myeloablative conditioning included 4.5 mg/kg ATG (thymoglobulin). High levels of ATG specificities capable of binding to T-and B-cell subsets were associated with a low likelihood of acute GVHD (aGVHD). High levels of these ATG specificities were associated with increased rates of viral but not bacterial or fungal infections. They were not associated with an increased risk of malignancy relapse; on the contrary, high levels of ATG specificities capable of binding to regulatory T cells and invariant NKT cells were associated with a low risk of relapse. In conclusion, high levels of ATG antibodies to Ag(s) expressed on T and B cells are associated with a low risk of aGVHD and a high risk of viral but not bacterial or fungal infections. These antibodies have neutral or beneficial effects on relapse.
INTRODUCTION
Polyclonal rabbit-anti-human thymocyte globulin (ATG, thymoglobulin, Genzyme) has been shown to decrease the likelihood of GVHD in both unrelated [1] [2] [3] [4] [5] [6] and related 7, 8 hematopoietic cell transplant recipients. Importantly, thymoglobulin and a similar drug, polyclonal rabbit-anti-human T cell line (Jurkat) globulin (ATG Fresenius), are capable of preventing not only acute GVHD (aGVHD) but also chronic GVHD (cGVHD), 1,5-7,9-11 a major cause of poor quality of life of transplant recipients long-term.
Consistent with that, we have recently shown that in patients receiving ATG at a relatively low dose (4.5 mg/kg) during myeloablative conditioning, high ATG levels early post transplant were associated with low risk of aGVHD and cGVHD. 12 ATG consists of polyclonal antibodies specific for Ags expressed on multiple immune-cell subsets, including T cells (including regulatory T cells (Tregs) and invariant NKT (iNKT) cells), B cells, natural killer cells, monocytes and DC. 13 Each of these subsets have been shown or suspected to have a role in the pathogenesis of GVHD. 14, 15 Theoretically, administration of ATG may be associated with an increased risk of relapse and infections. 1, 16 The role of the different antibodies within ATG in preventing GVHD and possibly increasing relapse or infections is unknown. Identifying the Ab(s) that prevent(s) GVHD versus the Ab(s) that increase(s) relapse or infections could enable purification and administration of the Ab(s) with anti-GVHD effect and not the antibodies mediating side effects. As a step toward identifying which Ab(s) within ATG has(have) the beneficial and not the side effects, here we set out to identify which ATG specificity (group of antibodies binding to one immune-cell subset) is primarily associated with a low likelihood of GVHD and which ATG specificity is primarily associated with relapse or infections.
PATIENTS AND METHODS
See Tables 1 and 2 , Figure 1 and Supplementary Online Material.
RESULTS

Variability in clearance of ATG specificities
The clearance of total ATG from serum has previously been shown to vary markedly from patient-to-patient. 2 Consistent with that, for each ATG specificity, there was a marked patient-to-patient variation in day 7 and 28 levels (Figure 2a and b) . Moreover, each ATG specificity appeared to be cleared at a different rate. On day 7 the serum levels were the highest for ATG specificities capable of binding to central memory (CM) CD4 T cells, CD4 À CD8 À T cells and iNKT cells (suggesting slow clearance of these specificities between days 0 and 7), and the lowest for ATG specificities capable of binding to neutrophils, monocytes and DCs (suggesting fast clearance of these specificities between day 0 and 7) (Figure 2a ). Between days 7 and 28 the clearance was the fastest for specificities capable of binding to CM CD4 T cells, CD4 À CD8 À T cells and iNKT cells, and the slowest for ATG specificities capable of binding to monocytes, neutrophils and DCs ( Figure 2c ). For each specificity, there was a significant difference in day 7 as well as day 28 levels compared with any other specificity (Po0.05, Mann-Whitney-Wilcoxon test). The high specificity-to-specificity variation in clearance and the high patient-to-patient variation in the clearance presented an opportunity for evaluating whether there are associations between specificity levels and outcomes.
ATG specificities and aGVHD In univariate analyses, patients who developed grade 2-4 aGVHD had significantly lower levels of the following ATG specificities in day 7 serum compared with patients who did not develop grade 2-4 aGVHD: capable of binding to naïve CD4 T cells, effector memory (EM) CD4 T cells, Tregs, total B cells, naïve B cells and mIgD þ CD27 þ (not isotype-switched) memory B cells (Table 3) . Similarly to day 7, the following ATG specificities were significantly lower in patients who developed aGVHD in day 28 serum: capable  of binding to total CD4 T cells, naïve CD4 T cells, EM CD4 T cells,  CM CD4 T cells, total CD8 T cells, naïve CD8 T cells, EM CD8 T (Table 3 ). All ATG specificities associated with aGVHD in univariate analyses were also significantly associated with aGVHD in multivariate analyses (Table 3 ). The highest relative risk (that is, X3) of developing aGVHD was for patients with low ATG specificities capable of binding to naive CD4 T cells, EM CD4 T cells and Tregs 
Acute GVHD  Grade 0  73  Grade 1  40  Grade 2  25  Grade 3  13  Grade 4 2 Good-risk disease/stage includes acute leukemia in first remission (n ¼ 54), CML in first chronic phase (n ¼ 10), myelodysplasia with o5% marrow blasts (n ¼ 14) and aplastic anemia (n ¼ 4). Poor-risk disease/stage includes myelofibrosis, lymphoma, multiple myeloma, CML in blast crisis, myeloproliferative disorders (with or without dysplasia), AML evolving from MDS or myeloproliferative disorder.
b Unrelated donors matched in 9-10/10 HLA alleles (n ¼ 76) or related donors matched in 8-9/10 HLA alleles (n ¼ 4). Patients who developed second malignancy (n ¼ 13), relapse (n ¼ 9), death (n ¼ 8) or lost to follow-up (n ¼ 1) before day 100.
d If diagnostic/distinctive features of cGVHD were present before day 100 in the absence of features typical for aGVHD, the disease was called cGVHD. e Aplastic anemia patients were excluded from analyses of relapse (n ¼ 4).
f Patients were followed until they developed graft failure, second malignancy (including PTLD), relapse or death or until they were lost to follow-up (defined as the last day on which medically meaningful information was available). 
Side scatter high and CD16 Flow cytometric data were acquired using FACS Aria flow cytometer/sorter. After sequential gating on the cell subset of interest (naïve CD4 cells on the left, DC/DC precursors on the right), phycoerythrin (PE, rabbit IgG) fluorescence was measured. This was done for each ATG level standard and each patient serum. Middle (standard curves): median PE fluorescence was plotted against ATG specificity level standard to construct the standard curve. Patient serum ATG specificity level was determined by extrapolation. Y axes display ATG specificity level in EUone EU of an ATG specificity (capable of binding to a cell subset) is the concentration of ATG binding to the cell subset within 1 mg/L total ATG. The serum levels for each ATG specificity were different (in this example, 1.07 EU for the ATG specificity for naïve CD4 T cells, and 0.02 EU for the ATG specificity for DC/precursors), suggesting that each specificity is cleared from serum (and presumably from the patient) at a different rate. Bottom (comparison plots for patients with vs without aGVHD): day 28 serum levels of the ATG specificity capable of binding to naïve CD4 T cells ('ATG specificity for naïve CD4 T cells') were compared by Mann-Whitney-Wilcoxon rank sum test between patients who developed grade 2-4 aGVHD and patients who did not (left). The same comparison was performed for the ATG specificity capable of binding to DC/precursors ('ATG specificity for DC') (right). Although there was a significant association of the levels of the ATG specificity for naïve CD4 T cells with aGVHD, there was no such association of the levels of the ATG specificity for DC/precursors.
( Table 3 ). aGVHD cumulative incidence curves for patients with low vs high levels of these specificities are shown in Figure 3 . A limitation of the above analyses is that only ATG specificities very much associated with aGVHD are identified but ATG specificities less associated with aGVHD are not. The latter ATG specificities might be identified as associated with aGVHD in a larger patient cohort. To show ATG specificities possibly associated with aGVHD, and ATG specificities possibly not associated with aGVHD, in Supplementary Table 2 we display ATG specificities for which there was a trend toward a higher level of that specificity in patients without than with aGVHD (univariate P value between 0.05 and 0.15, or univariate P value o0.05 but multivariate P value 0.05-0.15) and specificities for which there was no such trend (univariate P value 40.15 or multivariate P value40.15). ATG specificities in both day 7 and day 28 sera that were not associated with aGVHD were specificities capable of binding to monocytes, DC and neutrophils (Supplementary Table 2 ).
ATG specificities and cGVHD
We found no significant association between a single ATG specificity on day 7 or 28 and cGVHD. For all ATG specificities, median levels on both day 7 and 28 were lower (though not significantly) in patients who subsequently developed cGVHD compared with patients who did not (see examples in Figure 4 ). ATG specificities and relapse In univariate analyses, patients not developing relapse had significantly higher day 7 levels of ATG specificities capable of binding to Tregs, iNKT cells and DCs (Table 4) . In multivariate analyses, only ATG specificities capable of binding to Tregs and iNKT cells were significantly associated with relapse (Table 4 , Figure 4 ).
We next assessed if an ATG specificity was associated with relapse of lymphoid or myeloid malignancies. Relapse occurred in 11/49 patients with lymphoid malignancies (ALL (n ¼ 19), nonHodgkin lymphoma (n ¼ 19) and CLL (n ¼ 11)), and in 16 of 98 patients with myeloid malignancies (AML (n ¼ 58), myelodysplastic syndrome (n ¼ 20), myeloproliferative disorder (n ¼ 3) and CML (n ¼ 17)). In univariate analyses, no day 7 or day 28 levels of ATG specificities were associated with relapse of lymphoid malignancies. In both univariate and multivariate analysis, low day 28 (but not day 7) levels of ATG specificity capable of binding to monocytes were significantly associated with increased risk of relapse of myeloid malignancies (multivariate P ¼ 0.002, relative risk ¼ 3.27 for levels o0.0207 EU (equivalence units)).
ATG specificities and infections A total of 120 viral infections, 72 bacterial infections and 15 fungal infections occurred between day 7 and 179, in the 111 patients from whom we had day 7 sera. A total of 133 viral infections, 63 bacterial infections and 16 fungal infections occurred between day 28 and 179, in the 137 patients from whom we had day 28 sera. In univariate analyses, there was a significant positive correlation between the rate of viral infections between day 7 and 179 and day 7 levels of ATG specificities capable of binding to all T-cell subsets, all B-cell subsets, iNKT cells, DCs, monocytes and neutrophils (Table 5 ). All these associations were significant also in multivariate analyses (Table 5) . For day 28, high levels of ATG specificity capable of binding to DCs were significantly associated with low rates of viral, bacterial and fungal infections between day 28 and 179, both in univariate and multivariate analysis (Table 5) .
Concerning post-transplant lymphoproliferative disorder (PTLD), in both univariate and multivariate analyses, patients developing PTLD had significantly higher day 7 levels of ATG specificities capable of binding to most T-cell subsets (Table 6 ).
ATG specificities and survival There was no significant difference in the serum level of any ATG specificity between patients who died vs survived. As an example, we show the survival curve for the ATG specificity capable of binding to Tregs in Supplementary Figure 2 .
Correlation between levels of ATG specificities and cell counts Low serum level of an ATG specificity may be a reflection of a high absolute count of cells to which the ATG specificity can absorb. To evaluate this, we measured the counts of cell subsets (each corresponding to an ATG specificity) in the blood in 83 of the 137 patients on day 28 (the counts were too low to be measured on Figure 2 . ATG specificity levels in days 7 (a) and day 28 (b) sera and clearance of ATG specificities between days 7 and 28 (c). Levels of the specificities of ATG capable of binding to the immune-cell subsets shown were measured in day 7 sera (a) and day 28 sera (b day 7). For minor differences between the definitions of cell subset counts when measuring ATG specificities vs the cell subset counts, see Supplementary Table 3 . There were significant inverse correlations between ATG specificities capable of binding to T-cell and B-cell subsets and low counts or the corresponding T-and B-cell subsets (Table 7) .
DISCUSSION
Previous studies have shown that serum levels of ATG are inversely associated with the risk of GVHD. 3, 12 As ATG is polyclonal, the anti-GVHD effect may be mediated by a small portion of the antibodies. This study aimed to identify the specificities of ATG that are associated with GVHD, relapse or infections. In patient sera from day 7 and 28 we measured levels of 23 ATG specificities that were capable of binding to different immune-cell subsets that may have a role in GVHD, relapse and infections.
Development of aGVHD was associated with lower levels of ATG specificities capable of binding to T cells (including naïve and memory T cells, Tregs and iNKT cells) and memory B cells. Naïve T cells given with the graft have been identified as key initiators of aGVHD. [17] [18] [19] [20] However, we also found that ATG binding to CM and EM CD4 T cells was associated with the risk of aGVHD. This could be due to binding of ATG specificities to common surface Ags on naïve, CM and EM T cells, or due to the fact that alloreactive naïve CD4 T cells differentiate in the recipient into CM or EM T cells. Regarding Treg and iNKT cells, multiple studies 15, [21] [22] [23] [24] [25] (though not all [26] [27] [28] [29] ) have suggested their anti-GVHD role. In contrast, our results showed an association between high levels of ATG specificities capable of binding to Treg and iNKT cells and a decreased risk of aGVHD, suggesting a pro-GVHD role for Treg and iNKT cells. This counterintuitive result might be explained by overlapping surface Ag expression by Treg/iNKT cells and conventional (non-regulatory) T cells, or by ATG inducing Treg Figure 1 . The cutoff between low and high levels of ATG specificities was determined using ROC curve analysis. The cutoff with the largest sum of sensitivity and specificity was chosen. The RR expresses the fold risk for developing GVHD in patients with ATG specificity levels below the cutoff over the risk in patients with the ATG specificity levels above the cutoff.
ATG specificities associated with GVHD but not relapse M Hoegh-Petersen et al or iNKT cells (instead of killing/inhibiting them). 30, 31 Regarding B cells, both a pro-GVHD role and an anti-GVHD role of B cells has been described [32] [33] [34] [35] . As B cells can act as APCs, Ab-producing cells and regulatory cells, B cells probably act in multiple ways to either diminish of amplify the GVHD response.
In contrast to the well described pathophysiology of aGVHD, much less is known about the pathophysiology of cGVHD. 36 We did not find any significant associations between individual ATG specificities and the likelihood of developing cGVHD. This may be explained by the complexity of cGVHD pathogenesis. There may not be a single cell type that is most responsible for initiating or maintaining cGVHD. For all ATG specificities, median levels on both day 7 and 28 were lower in patients who subsequently developed cGVHD compared with patients who did not, even though statistical significance was not reached. Thus, the composite effect of multiple cell subsets may lead to cGVHD. Alternatively, tissue-residing cells (for example, macrophages, mast cells), specificities binding to which were The RR expresses the fold risk for developing relapse in patients with ATG specificity levels below the cutoff over the risk in patients with the ATG specificity levels above the cutoff.
ATG specificities associated with GVHD but not relapse M Hoegh-Petersen et al not measured here, might have a role in the pathogenesis of cGVHD. No ATG specificities had significantly higher levels in patients who subsequently relapsed. On the contrary, high levels of ATG specificities capable of binding to Treg and iNKT cells were associated with a low risk of relapse. The reason for most ATG specificities having relapse-neutral effect and some possibly having anti-relapse effect may be that hematological malignancy cells share Ags with thymocytes used for the production of ATG, and antibodies against the shared Ags cause apoptosis of the malignant cells. 37 This is supported by our finding that high levels of ATG specificities capable of binding to monocytes are associated with decreased likelihood of relapse of myeloid malignancies, as myeloid malignancies are expected to share many surface Ags with monocytes. In addition to the possible direct anti-tumor effect of ATG antibodies, some ATG specificities (for example, those capable of binding Treg or iNKT cells) might also disrupt immune regulatory networks in a way that positively affects graft-vs-leukemia/lymphoma reaction. For example, Tregs are known to inhibit anti-tumor immunity, 38, 39 and this may be theoretically reversed by anti-Treg antibodies within ATG.
Viral infection risk was increased in patients with high day 7 levels of all ATG specificities associated with aGVHD. This suggests that increased propensity to develop viral infections is an unavoidable side effect of all anti-GVHD ATG specificities. We identified a total of 120 viral infections. Of these the majority were CMV reactivations to above our threshold for preemptive therapy (n ¼ 37). The second most common viral infection was BK virus cystitis (n ¼ 30), and the third was PTLD (n ¼ 16). The remaining 37 viral infections were caused by parainfluenza (n ¼ 9), adenovirus (n ¼ 7), HSV (n ¼ 3), varizella zoster virus (n ¼ 3), human papilloma virus (n ¼ 3), rotavirus (n ¼ 3), rhinovirus (n ¼ 3), influenza (n ¼ 2), respiratory syncytial virus (n ¼ 2), parvovirus (n ¼ 1) and norovirus (n ¼ 1). Our patient cohort underwent no monitoring for EBV DNAemia. It is possible that with EBV DNAemia monitoring with preemptive or prompt therapy (rituximab, EBV-specific T cells or withdrawal of immunosuppressive drugs), the incidence of and mortality because of PTLD would be lower. 40, 41 Only three viral infections were fatal-PTLD in two cases and disseminated adenoviral infection in one case. In two of the three cases (one PTLD and one disseminated adenoviral infection), the patients had steroid-resistant aGVHD, so the poor antiviral immunity could have been due to the GVHD and/or its treatment rather than due to high ATG specificity levels on day 7 or day 28. Collectively, high levels of all anti-GVHD ATG specificities are associated with high rates of viral infections. However, the viral infections directly attributable to the high ATG levels are rarely fatal.
In our previous study on the levels of ATG binding to total lymphocytes, 12 we did not find a significant association with viral infections (except for PTLD), whereas in the current study we found multiple associations between levels of ATG specificities with viral infections. This is because of a difference in analyses. In the previous study, we analyzed whether patients with 1 or more infections had higher ATG levels than those with no infection in the post-transplant period of interest. In the present study, we analyzed whether there was a correlation between an ATG b The IRR shows the fold increase of the rate of viral infections in patients with ATG specificity levels above the cutoff over the rate of viral infections in patients with ATG specificity levels below the cutoff.
ATG specificities associated with GVHD but not relapse M Hoegh-Petersen et al specificity level and the rate of infections (number of infections per 365 patient-days at risk in the period of interest). The latter analysis is more sensitive for finding a significant association as it takes into account the infection rate (density) rather than simply whether infection(s) did vs did not occur. Consistent with that, when we analyzed whether there was a difference in ATG specificity levels between patients with no vs at least one viral infection between day 7(28) and 179 (using Mann-WhitneyWilcoxon test), no significant difference was found for any ATG specificity (data not shown). Also consistent with that we found a significant association between levels of 'total' ATG (capable of binding to total lymphocytes) on day 7 and day 7-179 viral infection rates (data not shown).
The most interesting ATG specificity identified is the one capable of binding to Tregs. High levels of this specificity were associated with decreased likelihoods of aGVHD and relapse and possibly a decreased likelihood of cGVHD. This is counterintuitive, as low Treg counts (assumed to result from high anti-Treg Ab levels) would be expected to lead to enhanced alloreactivity against both epithelia (promoting GVHD, which we did not find) and leukemia (promoting GVL, thus decreasing relapse, which we found). Perhaps, our understanding of Tregs is incomplete, as, counterintuitively, some studies suggest that Tregs have a pro-GVHD effect 26, 27 or that Tregs have an anti-cancer effect. 42, 43 A limitation of our study is the chance of finding spurious associations because of multiple comparisons. The chance is particularly pronounced when using in multivariate analysis the high vs low ATG cutoff determined as the receiver operating characteristic (ROC) curve point with the highest sum of specificity and sensitivity. We therefore performed additional multivariate analyses using cutoffs defined as medians. The ROC method is more likely to give spurious results, whereas the median method is more likely to miss true associations. As shown in Supplementary Tables 4-6, the results using the medians were similar to the results using ROC-determined cutoffs (Tables 3-5) . Thus, the main conclusion remains (that aGVHD is associated with low and viral infections with high levels of ATG specificities capable of binding to T and B cells).
Finally, we determined whether the levels of ATG specificities correlated with absolute cell counts of corresponding subsets. We found significant inverse correlations between levels of ATG specificities capable of binding to T-cell and B-cell subsets and counts of the corresponding subsets. Thus, it is possible that the low serum levels of the T-and B-cell-binding ATG specificities were a reflection of high counts of T or B cells.
In conclusion, antibodies within ATG that bind to T and B cells but not cytolytic (CD16 þ CD56 þ ) natural killer cells, monocytes, DC or neutrophils have anti-aGVHD effect. Antibodies that bind to The RR expresses the fold risk for developing PTLD in patients with ATG specificity levels above the cutoff over the risk in patients with the ATG specificity levels below the cutoff. The IRR (risk ratio) was calculated instead of RR due to non-convergence of log-binomial regression. Poisson regression with Huber-White sandwich robust variance was used to approximate the log-binomial model (See Statistics section in Methods)
Treg cells, iNKT cells and monocytes may have anti-leukemic effect. Importantly, the ATG specificities associated with low risk of aGVHD are not associated with increased risk of relapse, or bacterial or fungal infections. Correlation was determined with memory/effector CD8 T-cell counts.
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